An observational study For Investigating success in achieving clinical, structual and functional Remission and Sustaining efficacy with Tocilizumab

An observational study For Investigating success in achieving clinical, structual and functional Remission and Sustaining efficacy with Tocilizumab - ACTemra Investigation for remission introduction and VITality of remission . retrospective studY

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007086

Enrollment

200

Registered

2012-01-17

Start date

2008-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)RA patients who fulfilled the ACR classification criteria. 2) Rheumatoid arthritis diagnosed by ACR/EULAR new classification criteria for RA

Exclusion criteria

Exclusion criteria: No criteria

Design outcomes

Primary

Measure	Time frame
Percentages of three different remissions; clinical remission (the disease activity score using the 28 joint count [DAS28]-ESR), structural remission (modified total Sharp score [mTSS]), and functional remission (health assessment questionnaire [HAQ] at week 104 after tocilizumab treatment.	—

Secondary

Measure	Time frame
Maintenance period of clinical , structual and functional remission	—

Countries

Japan

Contacts

Public Contactkentaro hanami

University of Occupational and Environmental Health, Japan The First Department of Internal Medicine, School of Medicine

hanami@med.uoeh-u.ac.jp093-603-1611

Outcome results